Did you know, Dymista^® provides a 30 minute onset of action in clinical practice, with efficacy confirmed in real life

In a randomised, double-blind, placebo-controlled, 2-week trial involving 779 patients with moderate-to-severe seasonal allergic rhinitis, Dymista^® (MP29-02) showed a rapid onset of action, with statistically significantly greater improvement in the total nasal symptom score (TNSS) compared with placebo at 30 minutes after the first dose. The significant improvements in TNSS over placebo were sustained at each subsequent evaluation point during the 4-hour observation period.'

A study assessing the use, effectiveness and safety of Dyrnista^® in routine clinical practice reported that the effectiveness of Dyrnista^® observed in real-world setting was better than its efficacy in randomised controlled clinical trials. Results show in real-life, a rapid clinically relevant change, the rapid and complete response is what AR patients want.²  Patients (n=1781) assessed symptom control using visual analogue scale (VAS). The study showed that Dyrnista^® provides effective and rapid symptom control across all age groups (adolescents >_ 12 years, adults, and older patients) in a real-life setting with responder rates higher than those observed in controlled clinical trials.²